Home ›
Data Desk › Adage Capital Management, L.P. passes 5.0% of First Tracks Biotherapeutics Inc.
MarginsX Data Desk · 13G holders · Early-stage clinical trials · Private placement (PIPE)
Adage Capital Management, L.P. passes 5.0% of First Tracks Biotherapeutics Inc. In a Schedule 13G filed Nov 12, 2026, Adage Capital Management, L.P. reported 2.1 million shares of First Tracks Biotherapeutics Inc. (TRAX) as of Sep 30, 2026, 5.8% of the class. (SEC EDGAR, SCHEDULE 13G, Nov 12, 2026)
By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 12, 2026.
The threshold
A passive holder files this schedule once it owns more than 5.0% of a class. (SEC EDGAR, SCHEDULE 13G, Nov 12, 2026 )
The stock
The Nasdaq screener puts its market value at $2.0B. (Nasdaq stock screener, Nov 13, 2026 )
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/TRAX )
The filing on SEC EDGAR. (sec.gov )
The filing in the MarginsX reader. (MarginsX reader )
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.
Facts behind this article Fact Value Source As of Filer Adage Capital Management, L.P. Source 2026-11-12 Level 5 % Source 2026-11-12 Name First Tracks Biotherapeutics Inc. Source 2026-11-13 Form Schedule 13G Source 2026-11-12 Filed Nov 12, 2026 Source 2026-11-12 Shares 2,077,179 shares Source 2026-11-12 Who First Tracks Biotherapeutics Inc. (TRAX) Source 2026-11-13 Symbol TRAX Source 2026-11-13 Event date Sep 30, 2026 Source 2026-11-12 Pct 5.81 % Source 2026-11-12 Cap 1,979,043,137 USD Source 2026-11-13
Sources
Automated from SEC filings and market data. No AI. For information only. Not investment advice.
Discuss in MarginsX More from the Data Desk
More on MarginsX Companies in this article Topics Related Data Desk stories Every Data Desk article: /desk · RSS